Sanofi cancer executive jumps ship to Silicon Therapeutics

Winter has also had stints at Blueprint Medicines, Merck Research Laboratories and Exelixis.

Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon, becoming the latest in an increasingly long line of Big Pharma executives to join the early-stage life science stream.

Winter comes to the Boston-based company from Sanofi, where since 2013 he led its U.S. oncology research as site lead and research cluster head on overcoming immunosuppression.

This comes as Sanofi has once again been retooling its cancer R&D, bringing a deeper focus into key oncology areas after seemingly looking to scale down just a few years back.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Sanofi snubbed by Medivation, but the hunt goes on

Winter, also a Blueprint Medicines, Merck Research Laboratories and Exelixis alumnus, will work with Silicon and its “integrated physics-based drug discovery,” where it is looking to create small molecule therapeutics for diseases with challenging protein targets that are difficult to drug.

“Silicon Therapeutics has assembled a world-class team applying an industry-leading platform to address fundamental challenges for designing next-generation, breakthrough therapeutics,” said Winter.

“I’m excited to join Silicon Therapeutics’ mission that joins integrated excellence in physics-based simulations, chemistry and disease biology focused on making drugs that matter for patients.”

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.